Quotient (QTNT) Downgraded to “Hold” at ValuEngine
ValuEngine lowered shares of Quotient (NASDAQ:QTNT) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.
Several other brokerages have also recently issued reports on QTNT. BidaskClub raised shares of Quotient from a hold rating to a buy rating in a report on Thursday, June 21st. Zacks Investment Research cut shares of Quotient from a hold rating to a strong sell rating in a report on Saturday, June 2nd. Finally, BTIG Research reaffirmed a buy rating and issued a $10.00 target price on shares of Quotient in a report on Wednesday, May 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $11.50.
Shares of Quotient stock opened at $7.15 on Wednesday. The company has a debt-to-equity ratio of -3.11, a quick ratio of 1.59 and a current ratio of 2.11. Quotient has a 52-week low of $2.78 and a 52-week high of $9.02.
A number of institutional investors have recently modified their holdings of the business. Millennium Management LLC purchased a new position in Quotient in the second quarter worth about $3,699,000. Point72 Asset Management L.P. purchased a new position in Quotient in the second quarter worth about $3,179,000. Bellevue Group AG raised its holdings in shares of Quotient by 190.7% during the second quarter. Bellevue Group AG now owns 319,814 shares of the company’s stock valued at $2,568,000 after purchasing an additional 209,814 shares during the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Quotient during the second quarter valued at approximately $1,702,000. Finally, Knott David M raised its holdings in shares of Quotient by 61.6% during the first quarter. Knott David M now owns 160,000 shares of the company’s stock valued at $754,000 after purchasing an additional 61,000 shares during the last quarter. 49.31% of the stock is owned by institutional investors and hedge funds.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Story: Stock Symbols Definition, Examples, Lookup
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.